Winter Is Coming: What Can Novo Nordisk Do Next After Stock Fall?

Change must be due for Danish diabetes giant Novo Nordisk as the firm continues to flounder in the US thanks to a tough pricing environment, increased competition for insulin products and supposed cultural differences between European and American management teams.